SynAct Pharma AB

SynAct Pharma has a strong liquidity position, with a current ratio of 2.31 and cash and equivalents amounting to 51.55 million SEK, which is a significant portion of its total assets of 213.35 million SEK. The company's debt-to-equity ratio is 0.0, indicating no long-term debt obligations, and its total liabilities are relatively low at 61.06 million SEK compared to its total equity of 152.29 million SEK. The price-to-book ratio of 5.86 suggests that the market is valuing the company's equity at a premium relative to its book value.

The company's profitability metrics are negative, with a return on equity of -16.35% and a return on assets of -11.67%, indicating that it is not generating returns for its shareholders or effectively utilizing its assets. The operating income and net income are both negative, at -25.71 million SEK and -24.91 million SEK, respectively, reflecting ongoing losses. The EV/EBITDA ratio of -32.73 further underscores the company's unprofitable operations.

SynAct Pharma does not report revenue by segments or geographic regions, and its revenue is reported as 0.0 SEK, suggesting that it is in the early stages of commercialization or has not yet generated revenue from its products. The company's operations are likely concentrated in its core therapeutic areas of cancer and autoimmune diseases, as disclosed in its business description.

The company's growth trajectory is uncertain, as its revenue is currently reported as 0.0 SEK, and analyst estimates for the next period suggest a mean revenue estimate of 134.50 million SEK. The operating cash flow is negative at -11.19 million SEK, indicating that the company is not generating positive cash flow from its operations and may need to rely on external financing to fund its operations.

The risk assessment for SynAct Pharma indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is also low, and no adjustments have been applied to its valuation metrics. However, the company's negative operating and net income, along with its negative cash flow from operations, suggest that it may face financial challenges in the future.

Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's mean price target from analysts is 30.00 SEK, which is higher than its current market price of 16.8 SEK, suggesting that analysts have a positive outlook on the company's future performance. The mean EPS estimate is -1.52 SEK, which is an improvement from the last actual EPS of -2.17 SEK, indicating that the company may be on a path to reduce its losses.

Analysts project a 55.3% upside to a consensus price target of 30.0 SEK, signaling strong market confidence in future value.

The company maintains a zero debt-to-equity ratio, ranking in the top quartile compared to the pharmaceutical cohort median of 0.18.

Long-term debt decreased significantly from 3.1 million SEK in 2022 to 1.2 million SEK in 2026, reducing financial leverage risks.

Risk flags for dilution, liquidity, and credit are all rated low, suggesting a stable operational environment despite current losses.

The company generated zero revenue across all reported fiscal years from 2022 to 2026, indicating a complete lack of commercial sales.

Cash conversion of 0.45 is below the cohort median of 0.95, indicating inefficient capital utilization relative to peers.

Revenue kr 0.00; Operating income -kr 20.8M.

• ▍Revenue kr 0.00
• ▍Operating income -kr 20.8M

Revenue kr 0.00; Operating income -kr 24.3M.

• ▍Revenue kr 0.00
• ▍Operating income -kr 24.3M

Revenue kr 0.00; Operating income -kr 19.2M.

• ▍Revenue kr 0.00
• ▍Operating income -kr 19.2M

Revenue kr 0.00; Operating income -kr 25.7M.

• ▍Revenue kr 0.00
• ▍Operating income -kr 25.7M

Revenue kr 0.00; Operating income −29,5% YoY.

• ▍Revenue kr 0.00
• ▍Operating income −29,5% YoY
• ▍Net income −34,5% YoY
• ▍Free cash flow −34,7% YoY

Revenue kr 0.00; Operating income +59,9% YoY.

• ▍Revenue kr 0.00
• ▍Operating income +59,9% YoY
• ▍Net income +61,8% YoY
• ▍Free cash flow +62,0% YoY

Revenue kr 0.00; Operating income −112,4% YoY.

• ▍Revenue kr 0.00
• ▍Operating income −112,4% YoY
• ▍Net income −117,5% YoY
• ▍Free cash flow −119,1% YoY

Revenue kr 0.00; Operating income −37,8% YoY.

• ▍Revenue kr 0.00
• ▍Operating income −37,8% YoY
• ▍Net income −43,1% YoY
• ▍Free cash flow −41,8% YoY

Revenue kr 0.00; Operating income -kr 76.7M.

• ▍Revenue kr 0.00
• ▍Operating income -kr 76.7M